A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users

Daprodustat is a drug that is currently being developed as a treatment for renal anemia .
This study is to evaluate the efficacy and safety of daprodustat following a switch from
erythropoiesis-stimulating agent (ESA) in Japanese HD subjects with renal anemia who are
currently treated with ESA. The primary objective is to demonstrate non-inferiority of
daprodustat to darbepoetin alfa. This study is a 52-week, Phase III, double-blind,
active-controlled, parallel-group, multi-center study. The total duration of the study will
be approximately 58 weeks including screening and follow-up.